报价延迟最少15分钟:2026/04/28 07:30 EDT
盘前时段
|
||||
|
67.5537 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
66.17
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.73/3.77
|
|
企业价值
2.11B
|
| 资产负债 |
|
每股账面净值
10.52
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
427.54M
|
|
每股收益
7.05
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, drivingimproved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services. |
